News zum Sektor Gesundheit aus Hong Kong (China)

 

Artificial intelligence has shortened drug development from years to just 18 months, the founder of METiS TechBio said, as the AI-driven drug design start-up made its Hong Kong debut on Wednesday amid strong investor appetite for AI-related stocks in the city. “We see ourselves like a SpaceX-style company,” Lai Tsai-Ta, co-founder and CEO of METiS TechBio, who obtained a PhD from the Massachusetts Institute of Technology in the US, said. “We use AI algorithms to design a large number of......

CSPC PHARMA (01093.HK) announced that its self-developed SYS 6010 (an EGFR-targeting humanized monoclonal antibody-drug conjugate) has recently been included again by the National Medical Products Administration in the Breakthrough Therapy Designation list.The proposed indication is monotherapy for patients with locally advanced......

HELE, BG, AVT, BLMN and SEM are gaining attention as broker-favored stocks amid rising inflation and rate uncertainty....

SIMCERE PHARMA (02096.HK) announced that its self-developed LRRC15-targeting antibody-drug conjugate, SIM0613 for injection, has received a Clinical Trial Approval Notice issued by the National Medical Products Administration of China. The drug is planned to commence clinical trials for advanced solid tumors. (ec/w)~AASTOCKS Fin......

BELTSVILLE, Md., May 04, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer and Simcere Zaiming Pharmaceutical Co., Ltd., (Simcere) an oncology-focused biopharmaceutical company and a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096), today announced initiation of the dose optimization portion of the Phase 1 study of SIM0505, focusing on patients with platinum-resistant ovarian cancer. SIM0505 is an investigational antibody drug conjugate (ADC) comprised of an antibody that targets Cadherin-6 (CDH6) and a proprietary topoisomerase 1 inhibitor (TOPOi) payload....

SIMCERE PHARMA (02096.HK) announced that the resubmitted New Drug Application (NDA) for the innovative drug leudebacimab, developed in collaboration with Hong Kong Korno Biotherapeutics Company Limited, has been accepted for review by the National Medical Products Administration (NMPA). The drug is intended for the treatment of ......

CSPC PHARMA (01093.HK) announced that the marketing application in the European Union for its self-developed Amphotericin B Liposome for Injection (HC1507G2) has been approved, marking the first breakthrough for a Chinese liposomal formulation to be launched in Europe and a key step forward in the overseas expansion of high-end ......

CSPC PHARMA (01093.HK) announced that SYS6051, an antibody-drug conjugate (ADC) developed by the Group, has received approval from the US Food and Drug Administration (FDA) to commence clinical trials. The approved indication for this trial is advanced solid tumors.SYS6051 is an antibody-drug conjugate targeting human tissue fac......

FORM 8.3 PUBLIC DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) ** amendment has been made to remove the wording of a discretionary holding below section 2A , as this is not relevant ** 1. KEY INFORMATION   (a) Full name of Invesco Ltd. discloser: (b) Owner or   controller of interests and short positions disclosed, if different from 1(a): The naming of nominee...

Shares of WuXi AppTec surged both on the mainland and in Hong Kong after stronger-than-expected quarterly results lifted sentiment across the contract research and innovative drug sectors. The pharmaceutical company's Shanghai-listed shares rose by their daily limit of 10 per cent to close at 110.57 yuan on Tuesday, while its Hong Kong shares ended 14 per cent higher at HK$143.10, the highest since December 2021. The gains followed the company's market-beating first-quarter earnings released......

Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

China Resources Pharmaceutical (03320.HK) announced that Tiandong Pharmaceutical, a subsidiary of the group, has received the "Notice of Approval for Marketing Application of Chemical Active Pharmaceutical Ingredient" issued by the National Medical Products Administration for nadroparin calcium active pharmaceutical ingredient.N......

Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

China Resources Pharmaceutical (03320.HK) announced that its subsidiary China Resources Sanjiu (000999.SZ) released its first-quarter report. Total operating revenue was RMB8.13 billion, up 18.6% YoY. Net profit was RMB1.209 billion, down 9.2% YoY. (de/d)~AASTOCKS Financial NewsWebsite: www.aastocks.comThis article was automatic......

China Resources Pharmaceutical (03320.HK) announced that its subsidiary KUNYAO GROUP (600422.SH) released its first-quarter report. Total operating revenue was RMB836 million, down 48% YoY. The company recorded a net loss of RMB145 million, compared with a net profit of RMB114 million in the same period last year, representing a......

China Resources Pharmaceutical (03320.HK) announced that its subsidiary Tasly Pharmaceutical (600535.SH) released its first-quarter report. Revenue amounted to RMB2.165 billion, representing a YoY increase of 5.3%. Net profit reached RMB365 million, up 9.8% YoY. (de/d)~AASTOCKS Financial NewsWebsite: www.aastocks.comThis article......

There was HKD3.7 billion, HKD595.5 million and HKD289.8 million Southbound Trading net inflow to TRACKER FUND (02800.HK), CNOOC (00883.HK) and YOFC (06869.HK).There was HKD596 million, HKD502.6 million and HKD23.5 million Southbound Trading net outflow from BABA-W (09988.HK), SMIC (00981.HK) and AKESO (09926.HK).For Southbound T......

Simcere Pharmaceutical (02096.HK) announced that, for strategic optimization of its overall product commercialization strategy, the company has voluntarily withdrawn the New Drug Application (NDA) for ledeqibai monoclonal antibody and expects to resubmit the NDA within this month. The company will maintain close communication wi......

- Company to host conference call and webcast on May 7, 2026, at 8:00 a.m. ET (8:00 p.m. HKT)SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will report its first quarter 2026 financial results and provide recent corporate updates on May 7, 2026, before the opening of U.S. equity markets. The announcement will be followed by a conference call and webcast at 8:00 a.m. ET (8:00 p.m. HKT). Conference Call and Webcast Information The live webcast can be accessed by visiting the Company's website at http://ir.zailaboratory.com. Participants must register in advance of the conference call. Details are as follows: Registration link for webcast (preferred): https://edge.media-server.com/mmc/p/s7q4ox5h Registration link for dial-in: https://register-conf.media-server.com/register/BI802954894429400baf012f775762af29 All participants must use the link provided above to complete the online registration process in advance of the conference call. Dial-...

Eight mainland China-based companies – five of them biotech firms – passed listing hearings on the Hong Kong stock market in April, clearing the way for them to tap the city's deep liquidity. The influx, including an AI-driven drug discovery firm, a driverless technology developer and a maker of industrial robots, comes as the China Securities Regulatory Commission (CSRC) has been pushing private firms to list in Hong Kong. The market regulator has required companies that established so-called......